Targeted but not trouble-free: efalizumab and PML
- 1 August 2009
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 5 (8), 418-419
- https://doi.org/10.1038/nrrheum.2009.142
Abstract
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.This publication has 6 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseasesArthritis & Rheumatism, 2009
- Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?Autoimmunity Reviews, 2008
- Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapiesAnnals Of The Rheumatic Diseases, 2008
- Tumor necrosis factor inhibition: A part of the solution or a part of the problem of heart failure in rheumatoid arthritis?Arthritis & Rheumatism, 2008
- Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of diseaseArthritis & Rheumatism, 2007
- Natalizumab and PMLNature Neuroscience, 2005